Hopkins-HHMI Researchers Discover A Cause And Develop Test For Familial Colorectal Cancer

August 25, 1997

Researchers at The Johns Hopkins Medical Institutions and the Howard Hughes Medical Institute (HHMI) have identified the first known genetic mutation that causes familial colorectal cancer (FCC). The mutation causes the cancer through a completely novel mechanism once considered harmless, and is present in over one-half million Ashkenazi Jews, making it the most common cancer-related mutation now known. Using this discovery, researchers have developed a simple blood test to identify the mutation. Their findings are reported in the September 1, 1997, issue of Nature Genetics.

FCC accounts for between an estimated 15-50 percent of all colorectal cancers, but until now its genetic basis has been a mystery, according to Bert Vogelstein, M.D., Clayton Professor of Oncology, HHMI investigator, and co-director of the research. The mutation occurs in a cancer-causing gene called APC, which was previously identified by the same Hopkins researchers and had been linked to a less common form of hereditary colon cancer known as familial adenamatous polyposis (FAP).

The researchers believe that those who have this APC mutation have an estimated 20-30 percent lifetime risk of developing colorectal cancer. "Though they are at increased risk for the disease, it can be detected at an early and curable stage through regular diagnostic screening tests such as sigmoidoscopy and colonoscopy," says Frank Giardiello, MD, associate professor of medicine. Genetic counseling should be provided to all patients tested for the APC mutation, says Giardiello.

The Hopkins team says the newly identified APC mutation and the way it functions are unique. "The mutation itself is harmless. It does not actually change the function of the gene through the loss or insertion of genetic material, as is the case with most cancer-related genetic mutations," says Kenneth Kinzler, Ph.D., associate professor of oncology and co-director of the study. "Instead, what we've found is a subtle alteration in the genetic code that causes DNA instability and leads to hypermutability, or a cascade of mutations in surrounding sequences. These subsequent mutations are what actually causes the cancer," says Kinzler.

Genetic variations such as these, often referred to as polymorphisms, have long been known to researchers, but Vogelstein says they were thought to be junk pieces of DNA that had no bearing on disease. "The new research suggests that many of these polymorphisms will have to be re-examined in future studies to see if they also cause hypermutability," he says.

The researchers first identified the mutation in two unrelated individuals with benign colon tumors and family histories of colon cancer. They went on to study 766 Ashkenazim, believing the genetic similiarity of this group might provide insights into the causes of FCC. In fact, they found the mutation in over 6 percent of those studied.

The researchers then studied blood and tissue samples of 211 Ashkenazi Jewish colon cancer patients. They found that one in six of those patients who developed cancer prior to age 66, and one in eight of those who developed colorectal cancer at any age, had the mutation. The mutation was found in nearly one-third of Ashkenazi patients with a family history of colorectal cancer.

Patients with FCC generally have one or two family members with colon polyps or cancer and typically develop colon tumors in their fifties and sixties. While FCC is believed to account for a larger percentage of total colon cancers occurring in the U.S., it is often difficult to distinguish it from non-hereditary colon cancer. "Until now, its genetic basis has been a puzzle," says Vogelstein.

Although this study and the test are specific to the Ashkenazi Jewish population, the investigators say it provides important clues about familial colorectal cancer among in the general population as well. "Studying specific populations make the discovery of genetic mutations easier. These findings then serve as a paradigm for the general population," Kinzler says. "This is the first example of the kind of mutations that can cause FCC. It will have an important impact on cancer research because it proves that even a subtle alteration--something we used to think was inconsequential--can cause a predisposition to cancer. Now, we must go back and take a second look at things we may have ignored in past," he adds.

More than 130,000 cases of colon cancer are diagnosed in the U.S. each year. At least 15 percent, and perhaps up to half, of these cases are thought to have a hereditary component. FCC is the most common hereditary form. Familial Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colon Cancer (HNPCC), two other inherited syndromes well defined by Hopkins researchers in prior studies, account for another 3-5 percent of colon cancers. The remaining cases occur sporadically, with no familial or inherited genetic link, among the general population.

More than 95 percent of the estimated six million U.S. Jews are Ashkenazi. There are over 11.2 million Ashkenazi Jews worldwide, and the researchers estimate that more than 680,000 carry this new mutation. Testing for this specific mutation among this population is currently available at Hopkins. People of Ashkenazi Jewish heritage (typically those Jewish people whose decendents originally lived in Eastern Europe) with at least one first degree relative (a parent, sibling or child) who has had colon cancer and who are interested in more information about the gene test can call 410-955-4041. The gene test costs $200.

In addition to Vogelstein, Kinzler and Giardiello, other participants in this study include, Steve J. Laken, B.A., Gloria Petersen, Ph.D., Stephen B. Gruber, M.D., Ph.D., and Stanley Hamilton, M.D., from Hopkins; Carole Oddoux, B.A., and Harry Ostrer, M.D., from New York University Medical Center; and Heather Hampel, B.A., Arnold Markowitz, M.D., David Klemstra, M.D., Suresh Jhanwar, M.D., Ph.D., Sidney Winawer, M.D., and Kenneth Offit, M.D., from Memorial Sloan Kettering Cancer Center.

The research was funded by the Clayton Fund, the Lucille P. Markey Foundation in Cellular and Molecular Medicine, the National Foundation for Jewish Genetic Disease, the Society of Memorial Sloan Kettering Cancer Center, and the National Institutes of Health.
-end-
Due to licensing and research funding arrangements, the research described here is expected to financially benefit the Johns Hopkins University as well as the authors. Such arrangements are managed by the University in accordance with its conflict of interest policies.

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.